1215766-76-9

1215766-76-9 structure

Name: NBI 27914 hydrochloride
Chemical Name: 5-Chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-N'-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine hydrochloride (1:1)
CAS Number: 1215766-76-9
Molecular Formula: C₁₈H₂₁Cl₅N₄
Molecular Weight: 470.651
Catalog: Signaling Pathways GPCR/G Protein CRFR
Create Date: 2021-01-07 02:35:59
Modify Date: 2024-01-12 20:15:01
NBI-27914 (hydrochloride) is a selective Corticotropin-Releasing Factor 1 (CRF1) receptor antagonist with a Ki value of 1.7 nM[1][3][4].

Name	5-Chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-N'-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine hydrochloride (1:1)
Synonyms	4,6-Pyrimidinediamine, 5-chloro-N4-(cyclopropylmethyl)-2-methyl-N4-propyl-N6-(2,4,6-trichlorophenyl)-, hydrochloride (1:1) 5-Chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-N'-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine hydrochloride (1:1) MFCD05662281 5-Chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-N'-(2,4,6-trichlorophenyl)pyrimidine-4,6-diamine hydrochloride (1:1)

Description	NBI-27914 (hydrochloride) is a selective Corticotropin-Releasing Factor 1 (CRF1) receptor antagonist with a Ki value of 1.7 nM[1][3][4].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> CRFR Research Areas >> Neurological Disease
Target	Ki: 1.7 nM (CRF1 receptor)[4]
In Vivo	NBI 27914 (3~30 mg/kg; i.p.) hydrochloride attenuates the referred abdominal pain at the highest dose tested, it is efficacious both 4 and 24 h post-indomethacin dosing[1]. NBI 27914 (1~10 mg/kg; i.p.) hydrochloride dose dependently attenuates Freund's Complete Adjuvant-induced mechanical hyperalgesia. NBI 27914 (10 mg/kg) hydrochloride reverses the thermal hyperalgesia. NBI 27914 hydrochloride attenuates spinal nerve ligation-induced mechanical hyperalgesia and tactile allodynia with minimal effective doses equal to 5 and 10 mg/kg, respectively[1]. The higher doses of NBI 27914 hydrochloride blocks the behavioral seizures and prevents epileptic discharges in concurrent electroencephalograms recorded from the amygdala[2]. Animal Model: Male CD-1 mice (20~25 g)[1] Dosage: 3~30 mg/kg Administration: I.p. Result: Attenuated the referred abdominal pain at the highest dose tested, it was efficacious both 4 and 24 h post-indomethacin dosing.
References	[1]. Peng YL, et al. Central Neuropeptide S inhibits food intake in mice through activation of Neuropeptide S receptor. Peptides. 2010;31(12):2259-2263. [2]. Hummel M, et al. Pain is a salient "stressor" that is mediated by corticotropin-releasing factor-1 receptors. Neuropharmacology. 2010;59(3):160-166. [3]. Baram TZ, et al. The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res. 1997;770(1-2):89-95. [4]. Chen C, et al. Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J Med Chem.

Molecular Formula	C₁₈H₂₁Cl₅N₄
Molecular Weight	470.651
Exact Mass	468.020874

1215766-76-9	184241-44-9
1782228-59-4	855527-92-3
93965-89-0	1048649-80-4
61535-49-7	36362-09-1
669073-77-2	160901-63-3
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
1699491-55-8	6906-52-1
930439-75-1	1018584-77-4
1375289-11-4	888431-85-4